“In the stock game, winning means reaching a higher price.” However, striking the right chord each time needs a fair amount of luck.
No matter how disciplined and systematic investors are, equity market volatility will always manage to get the better of them. While a few lucky ones rake in the moolah, others fall victim to ad hoc strategies.
One could resort to commonly used techniques to find beaten down stocks that have the potential to recover faster than others. However, even such investment choices bear the risk of disappointment. Particularly, one could fall into the value trap if the hidden weaknesses in selected stock are not identified.
So, wouldn’t it be a safer strategy to look for stocks that are winners currently and have the potential to gain further?
Sounds good? Here’s how to execute it:
One should primarily target stocks that have recently been on a bull run. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.
If a stock is continuously witnessing an uptrend, there must be a solid reason or else it would have probably crashed. So, looking at stocks that are capable of beating the benchmark that they have set for themselves seems rational.
However, recent price strength alone cannot create the magic. Therefore, you need to set other relevant parameters to create a successful investment strategy.
Here’s how you should create the screen to shortlist the current as well as the potential winners.
Percentage Change in Price (4 Weeks) greater than zero: This criterion shows that the stock has moved higher in the last four weeks.
Percentage Change Price (12 Weeks) greater than 10: This indicates that the stock has seen momentum over the last three months. This lowers the risk of choosing stocks that may have drawn attention due to the overwhelming performance of the overall market in a very short period.
Zacks Rank 1: No matter whether market conditions are good or bad, stocks with a Zacks Rank #1 (Strong Buy) have a proven history of outperformance. You can see the complete list of today’s Zacks #1 Rank stocks here.
Average Broker Rating 1: This indicates that brokers are also highly hopeful about the stock’s future performance.
Current Price greater than 5: The stocks must all be trading at a minimum of $5.
Current Price/ 52-Week High-Low Range more than 85%: This criterion filters stocks that are trading near their respective 52-week highs. It indicates that these are strong enough in terms of price.
Just these few criteria narrowed down the universe from over 7,700 stocks to just 10.
Here we present five stocks out of those 10:
Verint Systems Inc. VRNT is a leading provider of analytic solutions for communications interception, digital video security and surveillance, and enterprise business intelligence. The company’s stock price has advanced 16.1% in the past four weeks. It has expected earnings growth of 12.8% for the current year. The Zacks Consensus Estimate for the current year has improved by 2.5% over the last 60 days.
Great Lakes Dredge & Dock Corp. GLDD provides dredging services in the United States and internationally. The company’s stock price has surged 24% in the past four weeks. It has expected earnings growth of 170.6% for the current year. The Zacks Consensus Estimate for the current year has improved by 2.2% over the last 60 days.
ANI Pharmaceuticals Inc. ANIP a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company’s stock price has risen 9.1% in the past four weeks. It has expected earnings growth of 17.8% for the current year. The Zacks Consensus Estimate for the current year has improved by 1.2% in the last 60 days.
Innospec Inc. IOSP develops, manufactures, blends, markets, and supplies specialty chemicals worldwide. The company’s stock price has increased 1.2% in the past four weeks. It has expected earnings growth of 3.5% for the current year. The Zacks Consensus Estimate for the current year has improved by 5.3% over the last 60 days.
BioSpecifics Technologies Corp. BSTC is a biopharmaceutical company that engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company’s stock price has advanced 0.3% in the past four weeks. It has expected earnings growth of 10.3% for the current year. The Zacks Consensus Estimate for the current year has improved by 8.3% in the last 60 days.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Great Lakes Dredge & Dock Corporation (GLDD) : Free Stock Analysis Report
Innospec Inc. (IOSP) : Free Stock Analysis Report
Verint Systems Inc. (VRNT) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
BioSpecifics Technologies Corp (BSTC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research